Posts filtered by tags: Boston top stories[x]


 

“At a Critical Juncture,” Desktop Metal Gets $160M From Koch Fund

Desktop Metal, a metal 3D-printing company, has raised $160 million in a funding round led by the technology arm of Koch Industries, the multinational industrial conglomerate led by billionaire philanthropists and right-leaning political donors Charles and David Koch.With the Series E funding from Koch Disruptive Technologies and other investors, Burlington, MA-based Desktop Metal says it has now raised a total of $438 million in venture capital financing since launching in 2015.Chase Koch, pre...
Tags: Google, Deals, Ge, Microsoft, Boston, Trends, Tech, Nike, Vc, 3d Printing, Ford, Venture Capital, Homeland Security, L'oreal, Toyota, Panasonic


Bevi Lands $35M for Smarter Water Cooler That Gets to Know You

The water cooler will see you now.The beverage engineers at Boston-based startup Bevi are hard at work building a drink dispenser that can call up the finest details of your workplace drink order. How much lime flavoring is enough? How effervescent should the carbonation be? What mix of vitamins should be added?“We see that people are getting more and more specific about what they want for themselves,” says Sean Grundy, co-founder and CEO of Bevi, a six-year-old Boston startup that makes a beve...
Tags: Deals, Sodastream, Boston, Trends, Startup, Tech, Vc, Rfid, Personalization, Pepsico, Boston Dynamics, Logmein, Trinity Ventures, Horizons Ventures, Todd Johnson, Kiva Systems


Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

[Updated 12:35pm ET with comments from Michael Gilman, Obsidian CEO, see below.] Bristol-Myers Squibb’s huge proposed buyout of Celgene earlier this month has left many in biotech circles concerned that the Summit, NJ, drugmaker’s days of creative, aggressive dealmaking with smaller companies might be over. So far, however, that isn’t the case.Two Boston-area biotechs, Kyn Therapeutics and Obsidian Therapeutics, announced deals this morning with Celgene (NASDAQ: CELG). Both partnerships bring C...
Tags: Deals, Boston, Cancer, Trends, Immunotherapy, Biotech, Life Sciences, Celgene, Bristol-myers Squibb, Obsidian, National blog main, New York blog main, New York top stories, Boston blog main, National top stories, Boston top stories


Boston Tech Watch: Nantucket, Lionbridge, Nano-C, Barac & Quick Base

Nantucket entrepreneurs welcome, and acquisitions abound. There are also new owners, new offices and new money in the bank for Boston-area technology companies this week. Read on for the details.—Sense, the Cambridge, MA-based home electricity management technology startup, has partnered with Swiss utility technology company Landis+Gyr to put Sense’s technology in Landis’ Internet-of-things platform, the companies said. In addition, Landis+Gyr joined Sense’s previously announced $18 million Ser...
Tags: Translation, Deals, Startups, Internet Of Things, UK, New York, Entrepreneurship, Germany, Boston, Trends, Tech, Cybersecurity, Vc, Paris, Venture Capital, Cambridge


IBM Vets Launch Sonrai Security, Eyeing Multi-Cloud “Complexity”

Businesses racing faster and faster to put their data and applications into multiple cloud services will soon have to figure out how to keep an eye on it all. Start thinking about the hundreds of users, the dozens of accounts, and the handful of different cloud services that don’t always speak the same language, and the job of monitoring and securing it all quickly gets complicated.This is the problem that Brendan Hannigan and Sandy Bird are attacking with their New York-based company Sonrai Se...
Tags: Google, Amazon, Deals, Startups, Open Source, Cloud, New York, Microsoft, Identity, Azure, Trends, Tech, Cisco, It, Cybersecurity, Vc


A VC’s Take: Global Volatility Hurts U.S. Venture Ecosystem

As Xconomy’s editors looked back at the year just passed, we asked technology leaders to comment on the trends they’d observed in 2018, and the developments they expected in 2019. Some leaders responded with their views on the business impact of the Trump era, pointing to specific policy positions such as tax code revisions, curbs on immigration, and the decision by federal regulators to roll back net neutrality requirements on telecom carriers.Alex Niehenke, a partner at Foster City, CA-based ...
Tags: Startups, Mobile, Hardware, Net Neutrality, Internet, Entrepreneurship, China, Russia, Funding, Immigration, San Francisco, Trends, Tech, Investment, Eu, Web


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders


Boston Tech Watch: Boston Metal, TaxJar, ClimaCell, & WithMe Health

A bunch of startups started 2019 off on the right foot taking big checks cut by investors that continue the boom from 2018. Read on for more.—Weather forecast company ClimaCell says its high-resolution data is now available in 40 countries, including India. In October, the Boston-based startup raised $45 million, pushing its total venture capital haul to $65 million, and since then, it added another $5 million from GXP Investments, an arm of Kansas power utility Great Plains Energy, and Nationa...
Tags: Deals, Startups, Boston, India, Israel, Trends, Tech, Mit, Bill Gates, Venture Capital, Cambridge, Kansas, National Grid, Worcester, Affectiva, Wells Fargo


Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown

The partial government shutdown may have diminished staffing at the SEC, but it hasn’t dimmed the hopes of biotech firms hoping to go public. On Friday, Kaleido Biosciences and Cirius Therapeutics both filed paperwork for their respective initial public offerings with the securities regulator.While it’s operating with “very limited staff” due to the shutdown, the SEC’s electronic system for regulatory filings is still up and running. Kaleido and Cirius join a handful of biotechs that have filed...
Tags: Startups, Drugs, Ipo, Boston, Trends, Investing, SEC, Biotech, Government Shutdown, Microbiome, Life Sciences, Clinical Trials, Frazier Healthcare Partners, National blog main, Boston blog main, Boston top stories


Uncertainty Grows for Biotech as Government, FDA Shutdown Drags On

The partial government shutdown could soon become the longest shutdown in history, and biotech firms that have submitted regulatory filings are facing greater uncertainty about their future plans. More than 40 percent of FDA workers and thousands at the SEC are furloughed, and FDA Commissioner Scott Gottlieb is resorting to Twitter to post updates about how his agency is using its fast-dwindling funds. Here’s a roundup of how the partial government shutdown is affecting the FDA.On Tuesday, Gott...
Tags: Startups, Ipo, Trends, SEC, Fda, National, Biotech, Government Shutdown, Shutdown, Life Sciences, Clinical Trials, NDA, Gottlieb, Scott Gottlieb, National blog main, New York blog main


FAANG, Public Trust, Valuations, in 2019: The Read from Menlo Ventures

The market caps of some of the most successful tech titans reach as high as $1 trillion. Yet in 2018, perceptions about these dominant companies often reflected uneasiness and doubt—and for some, so did their stock performance.Maybe the mood shift has to do with the fact that the public and government leaders no longer evaluate these tech giants based solely on their spectacular market growth and multi-billion-dollar valuations, but also on the effects of their products, which are woven into al...
Tags: Apple, Google, Amazon, Startups, Facebook, Uber, Microsoft, Privacy, Entrepreneurship, Ipo, Russia, Funding, San Francisco, Trends, Tech, Vc


Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ

When Black Diamond Therapeutics emerged from stealth mode last month with $20 million in backing and a handful of preclinical cancer drugs, the company signaled that another financing was in the works for 2019. That day is here.Black Diamond announced late Wednesday that it has closed $85 million in Series B financing, which the company says it will use to advance its top drug candidates into human testing within the next two years.Black Diamond was incubated within the Switzerland drug discove...
Tags: Deals, Startups, Boston, Cancer, Trends, Venture Capital, Switzerland, Biotech, Drug, New Enterprise Associates, Life Sciences, Black Diamond, Clinical Trials, Allosteric, Versant Ventures, National blog main


Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests

Beta Bionics, a startup developing a medical device that monitors and manages blood sugar levels in diabetes patients, has closed $63 million to back late-stage clinical tests of its AI-powered technology.The cash tops off a Series B round of funding announced last year. The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) among its investors and partners, says the capital will support Phase 3 studies of its device this year, and if all goes w...
Tags: Deals, Startups, Boston, Trends, Investing, Vc, Software, Diabetes, Venture Capital, Fda, Biotech, Novo Nordisk, Medical Device, Wearable Devices, Medtech, Life Sciences


Smooth-Driving Startup ClearMotion Gets $115M for Production Push

Auto technology startup ClearMotion says its active suspension system promising buttery-smooth rides on bumpy terrain is ready for prime time.The Boston-area business says it raised a $115 million Series D funding round led by Franklin Templeton Investments and it is working with a handful of automotive manufacturers to commercialize the product.ClearMotion developed a car suspension system it likens to noise-cancelling for potholes and the like that was based on research audio technology compa...
Tags: Deals, Microsoft, Boston, Trends, Tech, Mit, Vc, Automotive, Data Science, Venture Capital, Machine Learning, Mobility, Birmingham, Bose, Qualcomm, BRIDGESTONE


The Power Combo of A.I. Devices with Cloudlets Comes with Cyber Risks

When we have a chance to view it from a distance, the year 2018 may be seen as a period when innovations in a number of technological fields came together to transform not only the future of computing, but also the very structure of the Internet.First, entrepreneurs vying to invent self-driving vehicles, virtual assistants, and intelligent industrial machines created a hunger for more powerful semiconductors that could enable scattered devices to take over sophisticated calculations powered by ...
Tags: Startups, Mobile, Cloud, Hardware, Internet, Entrepreneurship, Funding, San Francisco, Trends, Tech, Web, It, Cybersecurity, Ransomware, Vc, Software


Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More

The flow of biotech news is particularly heavy today, and for good reason. The annual J.P. Morgan Healthcare Conference, one of the biggest gatherings for the biopharmaceutical industry, kicked off today in San Francisco, and many companies, whether they’re speaking at the event or not, use this time to get their news out.Xconomy is on the ground covering the conference this week. In the meantime, here’s a short roundup of biotech news announced today.DEALS AND DATA—Eli Lilly (NYSE: LLY) is pay...
Tags: Deals, Startups, San Francisco, Trends, Investing, Vc, Venture Capital, Fda, National, GlaxoSmithKline, Biotech, Postpartum Depression, Life Sciences, Clinical Trials, Celgene, Gilead Sciences


Humatics Raises $28M Round to Advance Spatial Intelligence Platform

Humatics, the Waltham, MA-based startup working on microlocation technology for use in robots and autonomous vehicles, today announced that it has raised $28 million in a Series A1 round.The investment was led by Tenfore Holdings, with participation from Blackhorn Ventures, JCI Ventures (the venture arm of Johnson Controls), and all major investors from Humatics’ 2017 Series A round, including Fontinalis Ventures, Airbus Ventures, Lockheed Martin Ventures, and Presidio Ventures. The two rounds ...
Tags: Deals, Startups, Entrepreneurship, Boston, Trends, Mit, Vc, Software, Innovation, Venture Capital, Gps, Series A, Industrial Robots, Waltham, Johnson Controls, Airbus Ventures


Frequency Nabs $42M for Hearing Loss Drugs, Clinical Data On The Way

Hearing loss drug development continues to attract investment, with Frequency Therapeutics announcing today that it has brought in $42 million in a Series B financing to help it move its treatment through clinical testing.Boston area-based Frequency is working on small molecule drugs that stimulate the growth of dormant stem cells in the body, and its lead drug, FX-322, targets key sensory cells in the inner ear. The drug, which is injected into the ear, is in an early-stage clinical trial, and...
Tags: Deals, Boston, Funding, Trends, Venture Capital, Biotech, Hearing Loss, Series B, Life Sciences, National blog main, Boston blog main, Boston top stories, Decibel Therapeutics, Frequency Therapeutics, Akouos


Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer

A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer. The first PARP inhibitor was approved in 2014. That drug, and others that followed, block a PARP enzyme that plays a key role in this repair process. But it turns out there’s more than one type of PARP—17, to be exact. Ribon Therapeutics aims to target other PARPs with small molecule drugs, and the Boston-area startup has raised $65 million in financing to bring its ...
Tags: Deals, Startups, Boston, Cancer, Funding, Trends, Venture Capital, Astrazeneca, Biotech, Series B, Life Sciences, Oncology, Celgene, Olaparib, Osage University Partners, National blog main


Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy, and more. You’ll find a few of our favorite stories in this review of some of the year’s best from across the Xconomy network. Topics ranged from the worries over CRISPR genome editing and Wild West biohacking, to Nobel Prize-fueled drug approvals and the headaches around drug prices (even for drugs meant to cure headaches).What will make our Best of 2019 list? You...
Tags: Ipo, Trends, CMO, Merck, Ceo, Vc, Lung Cancer, Fundraising, Venture Capital, M&a, Private Equity, Fda, National, Manufacturing, Immunotherapy, Abbvie


In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B

Bristol-Myers Squibb has agreed to acquire Celgene in a deal that would create one of the largest biopharma organizations in the world and send ripples throughout the life sciences sector.Bristol (NYSE: BMY) on Thursday morning inked a deal to buy Celgene (NASDAQ: CELG) in a deal that values the Summit, NJ, drugmaker at $74 billion, or $102.43 per share. Celgene shareholders will get $50 in cash and one Bristol share for each Celgene share they own. They’ll also get one tradeable contingent val...
Tags: Deals, Trends, Merck, M&a, Fda, National, Bristol, Biotech, Life Sciences, Celgene, Bristol-myers Squibb, KEYTRUDA, CVR, Opdivo, Orencia, Revlimid


Tiburio Launches from Cydan with $31M to Tackle Pituitary Tumors

Biotech startup creator Cydan is unveiling a new company, Tiburio Therapeutics, which is backed by $31 million to support its work on treatments for rare endocrine diseases.Cambridge, MA-based Cydan was started by New Enterprise Associates (NEA) six years ago to scour the world for compounds that can be turned into rare disease treatments, and to form companies around the most promising drug candidates.Tiburio’s lead drug, TBR-760, was licensed from Ipsen, which had developed the drug for a typ...
Tags: Deals, Drugs, Boston, Trends, Startup, Investing, Venture Capital, Cambridge, Fda, Biotech, New Enterprise Associates, Life Sciences, Clinical Trials, New Enterprise Associates NEA, Alexandria Venture Investments, Ipsen


MyoKardia Goes Solo as Sanofi Ends Precision Heart Drug Deal

MyoKardia rode a partnership with Sanofi to the public markets a few years ago. But the two companies are cutting ties today, with MyoKardia regaining full rights to its drug programs and assuming all the upside—and risk—of their success or failure.MyoKardia (NASDAQ: MYOK) said the deal, which started in September 2014, will wrap up in April. At that point, the South San Francisco, CA-based firm will fully control all of its experimental drugs, including the heart disease drugs mavacamten and M...
Tags: Deals, San Francisco, Trends, Vc, Biotech, Life Sciences, Clinical Trials, Sanofi, South San Francisco CA, National blog main, Boston blog main, San Francisco blog main, San Francisco top stories, Third Rock Ventures, Boston top stories, MYOK


Atlas Venture Bags $250M For New Growth Capital Fund

Atlas Venture says it has raised a $250 million fund meant to continue backing its startups as they grow.The Cambridge, MA, life sciences venture firm, known for seeding and incubating biotech startups, will use the new “Atlas Venture Opportunity Fund I” to invest in portfolio companies that have progressed to a Series B round and beyond. The fund complements Atlas’s existing funds—most recently a $350 million haul in June 2017—which it uses to seed new biotechs. The new fund will be run by the...
Tags: Deals, Startups, Boston, Trends, Atlas, Vc, Fund, Life Sciences, Atlas Venture, National blog main, Boston blog main, Boston top stories, Atlas Venture Opportunity Fund


New Year to Bring New Data Security Threats, Cyber Investor Warns

Bob Ackerman is one of the venture capitalists whose funding has long fed the growth of the burgeoning cybersecurity industry. So, you might imagine that his outlook on data protection for 2019 would be more optimistic than in past years, because businesses now take advantage of a broad choice of security services to protect themselves.Ackerman (pictured) is founder and managing director of San Francisco-based VC firm AllegisCyber, and co-founder of Fulton, MD-based DataTribe, which helps launc...
Tags: Startups, Mobile, Facebook, Hardware, Internet, Entrepreneurship, China, Russia, Funding, San Francisco, Trends, Tech, Web, It, Malware, Cybersecurity


From Alnylam to Zayner: Xconomy’s Top Innovation Stories of 2018

2018 was a year of ups and downs for the business and technology community. It was a year of big exits—both IPOs and acquisitions—for tech and life sciences companies. Venture funding remained strong, but more money went to fewer (and later-stage) companies overall. As the year winds down, we’re reflecting on the big innovation trends and developments that will carry over to next year.Storylines in various sectors helped shape the overall narrative in 2018. Cell and gene therapies, cancer immun...
Tags: Deals, Startups, Technology, Cloud Computing, Trends, Tech, IPOs, It, People, Cybersecurity, Analysis, Vc, Software, Bitcoin, Bill Gates, Innovation


CFOs: Prepare To Become Your Company’s Data Czar This Year

In mid-2018, Tom Bogan was the leader of business planning software company Adaptive Insights as it planned its own next steps. The Palo Alto, CA-based company was on the point of raising about $115 million in a June IPO that would have set its market value at around $705 million, according to PitchBook.But like Dustin Hoffman in “The Graduate,” the big enterprise software company Workday lured Adaptive Insights away from the IPO altar with a more attractive deal—a $1.55 billion acquisition off...
Tags: Deals, Startups, Cloud, Internet, Entrepreneurship, Ipo, Funding, San Francisco, Trends, Tech, Web, It, Excel, Software, Data Science, Innovation


Boston A.I. Leaders Call for Focus on Diversity, Global Mindset in 2019

It was an eventful year for the artificial intelligence industry.The sector saw more big venture capital deals and acquisitions, while researchers kept plugging away on technology advances. Meanwhile, A.I. developers continued to grapple with issues around transparency, trust, and ethics.As part of Xconomy’s series of year-end posts, we asked a pair of CEOs of Boston-area A.I. software startups to reflect on the trends that defined the sector in 2018—and where things might be headed in 2019. He...
Tags: Startups, Boston, Trends, Tech, Diversity, Mit, Vc, Artificial Intelligence, Software, Ethics, Facial Recognition, Affectiva, Rana el Kaliouby, Neurala, National blog main, New York blog main


Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio

Microbiome drug developer Vedanta Biosciences has raised $27 million in funding to press forward with clinical trials for four therapeutic candidates.Vedanta’s experimental treatments are compositions of live bacteria that the Cambridge, MA, company says trigger a targeted immune response. By shifting the ecosystem of gut bacteria, Vedanta says its therapies can potentially treat autoimmune and allergic diseases, as well as cancer.The company’s most advanced drug candidate, VE303, has started a...
Tags: Deals, Startups, Drugs, Boston, Cancer, Trends, Investing, Venture Capital, Cambridge, Biotech, Microbiome, Ubiome, Life Sciences, Clinical Trials, Nivolumab, Vedanta


Relay Raises $400M to Kick Protein Motion Drug R&D into High Gear

The line dividing biotechnology and high tech is blurring as drug companies find new ways to apply computer advances in the hunt for new drugs. Relay Therapeutics uses these techniques to better understand a protein’s role in disease and develop a drug to address it. Cancer is Relay’s first target.The Cambridge, MA, biotech is moving forward with its plans to advance its lead cancer programs into clinical trials with an additional $400 million it raised in a Series C round of funding led by the...
Tags: Deals, Drugs, Boston, Cancer, Trends, Tech, Investing, It, Software, Venture Capital, Cambridge, Machine Learning, Biotech, Life Sciences, Clinical Trials, Alexandria Venture Investments